Abstract
Prostate cancer is the most frequently diagnosed malignancy and the second leading cause of cancer deaths in American men. Although many treatment measures such as androgen deprivation, radiation therapy, and cryoablation exist for primary prostate cancer, there is currently no effective treatment for patients presenting advanced or metastatic stages of the disease. Molecular therapy offers an attractive approach to the treatment of primary prostate cancer because the prostate is not a life-sustaining organ, and a number of tissue specific promoters can be used for prostatic gene expression following relatively straightforward delivery routes. This review discusses the general molecular therapy applications in the context of prostate cancer, and most importantly, identifies the prostate apoptosis response-4 (Par-4) gene, which exclusively induces apoptosis in cancer cells and not normal cells, as a prospective molecule for therapy of the disease.
Keywords: par-4, prostate cancer, apoptosis, molecular therapy
Current Drug Targets
Title: Par-4 for Molecular Therapy of Prostate Cancer
Volume: 4 Issue: 3
Author(s): James Butler and Vivek M. Rangnekar
Affiliation:
Keywords: par-4, prostate cancer, apoptosis, molecular therapy
Abstract: Prostate cancer is the most frequently diagnosed malignancy and the second leading cause of cancer deaths in American men. Although many treatment measures such as androgen deprivation, radiation therapy, and cryoablation exist for primary prostate cancer, there is currently no effective treatment for patients presenting advanced or metastatic stages of the disease. Molecular therapy offers an attractive approach to the treatment of primary prostate cancer because the prostate is not a life-sustaining organ, and a number of tissue specific promoters can be used for prostatic gene expression following relatively straightforward delivery routes. This review discusses the general molecular therapy applications in the context of prostate cancer, and most importantly, identifies the prostate apoptosis response-4 (Par-4) gene, which exclusively induces apoptosis in cancer cells and not normal cells, as a prospective molecule for therapy of the disease.
Export Options
About this article
Cite this article as:
Butler James and Rangnekar M. Vivek, Par-4 for Molecular Therapy of Prostate Cancer, Current Drug Targets 2003; 4 (3) . https://dx.doi.org/10.2174/1389450033491163
DOI https://dx.doi.org/10.2174/1389450033491163 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adenovirus Mediated Herpes Simplex Virus-Thymidine Kinase/Ganciclovir Gene Therapy for Resectable Malignant Glioma
Current Gene Therapy Molecular Pathways of Interferon-Stimulated Gene 15: Implications in Cancer
Current Protein & Peptide Science Activation and Control of CNS Innate Immune Responses in Health and Diseases: A Balancing Act Finely Tuned by Neuroimmune Regulators (NIReg)
CNS & Neurological Disorders - Drug Targets Performance and Effect of Automatic Contouring in Automatic Adaptive Planning for Prostate Cancer Volumetric Modulated Radiotherapy
Recent Patents and Topics on Imaging (Discontinued) Essential Oils: Extraction Techniques, Pharmaceutical And Therapeutic Potential - A Review
Current Drug Metabolism Chemistry of Tumour Targeted T1 Based MRI Contrast Agents
Current Topics in Medicinal Chemistry Human 90 kDa Heat Shock Protein Hsp90 as a Target for Cancer Therapeutics
Current Chemical Biology The Role of PET/CT and SPECT/CT in Oncology Drug Development
Current Molecular Imaging (Discontinued) Effects of Salinomycin on Cancer Stem Cell in Human Lung Adenocarcinoma A549 Cells
Medicinal Chemistry HSV-1 Viral Oncolysis and Molecular Imaging with PET
Current Cancer Drug Targets Editorial from Guest Editor (DNA Methylation: A Target for Current and Future Therapies?)
Epigenetic Diagnosis & Therapy (Discontinued) Analysis of Differential Gene Expression Based on Bayesian Estimation of Variance
Current Bioinformatics Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies
Current Neuropharmacology Therapeutic Benefits of <i>Piper nigrum</i>: A Review
Current Bioactive Compounds The High Throughput Biomedicine Unit at the Institute for Molecular Medicine Finland: High Throughput Screening Meets Precision Medicine
Combinatorial Chemistry & High Throughput Screening Multigene Methylation Biomarker Analysis in Prostate Cancer
Epigenetic Diagnosis & Therapy (Discontinued) An Overview of Current Screening and Management Approaches for Prostate Cancer
Current Drug Metabolism From Protein to Peptides: a Spectrum of Non-Hydrolytic Functions of Acetylcholinesterase
Protein & Peptide Letters Chemotherapeutic Effects of Acridine Derivatives
Medicinal Chemistry Reviews - Online (Discontinued) Diabetes and Pancreas: Why So Difficult? Potential Mechanisms of Elevated Serum Pancreatic Enzymes
Current Medicinal Chemistry